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Abstract 
Chronic diseases (i.e., Noncommunicable Diseases), mainly cardiovascular disease, 
cancer, respiratory diseases and type-2-diabetes, are now the leading cause of death, 
disability and diminished quality of life on the planet. Moreover, these diseases are 
also a major financial burden worldwide, significantly impacting the economy of 
many countries.  Healthcare systems and medicine have progressively improved upon 
the ability to address infectious diseases and react to adverse health events through 
both surgical interventions and pharmacology; we have become efficient in delivering 
reactive care (i.e., initiating interventions once an individual is on the verge of or has 
actually suffered a negative health event).  However, with slowly progressing and 
often ‘silent’ chronic diseases now being the main cause of illness, healthcare and 
medicine must evolve into a proactive system, moving away from a merely reactive 
approach to care. Minimal interactions among the specialists and limited information 
to the general practitioner and to the individual receiving care lead to a fragmented 
health approach, non-concerted prescriptions, a scattered follow-up and a suboptimal 
cost-effectiveness ratio. A new approach in medicine that is predictive, preventive, 
personalized and participatory, which we label here as “P4” holds great promise to 
reduce the burden of chronic diseases by harnessing technology and an increasingly 
better understanding of environment-biology interactions, evidence-based 
interventions and the underlying mechanisms of chronic diseases. In this concept 
paper, we propose a ‘P4 Health Continuum’ model as a framework to promote and 
facilitate multi-stakeholder collaboration with an orchestrated common language and 
an integrated care model to increase the healthspan.   
Key Words: Systems medicine; P4 medicine; Healthspan; Exercise; Nutrition; 
Wellness; Allostasis; Allostatic load; Systems biology 
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Abbreviation 
 
BP: Blood pressure 
 
CVD: Cardiovascular disease 
 
DM: Diabetes mellitus  
 
LCHD: Life Course Health Development  
 
NCD: Noncommunicable disease 
 
PA: Physical activity 
 
P4: Preventive, Predictive, Personalized and Participatory 
 
P4H: P4 Health 
 
QoL: Quality of life 
 
WHO: World Health Organization  
 
 
Disclosure:  None. 
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Introduction 
Chronic diseases, otherwise known as noncommunicable diseases (NCDs), 
represent the major global health problem of the 21
st
 century.
1-4
 The major chronic 
diseases listed by World Health Organization (WHO) are cardiovascular disease 
(CVD), cancer, chronic respiratory diseases and diabetes mellitus (DM); 
neurodegenerative disorders are also a significant concern. Chronic diseases are the 
world’s leading cause of health burden and mortality and are continuing to increase in 
both incidence and prevalence.
1, 4, 5
 Moreover, chronic diseases are a major cause of 
poverty and hinder economic development.
6
 Chronic diseases share common risks 
including socio-economic factors, cluster in co-morbidities and are intertwined with 
aging.
4, 7
 The challenge for chronic diseases in the 21
st
 century is to deal with their 
complexity and the often ‘silent’ transition from health to disease with a late onset of 
symptoms which can delay treatment and interventions and to shift toward 
prevention. 
Fortunately, the majority of chronic diseases can be prevented or delayed until 
significantly later in life through interventions such as adoption of a healthy lifestyle 
throughout the lifespan resulting in an extended healthspan (i.e., the duration of one’s 
life spent in a state of wellness, free of disease).
8-12
  Monitoring and maintaining 
normal values for key health metrics, such as blood pressure (BP), lipids, and blood 
glucose also play a primary role in reducing chronic disease risk.
5
   Moreover, as we 
gain a better understanding of genomics and more importantly the interaction between 
genomics, lifestyle, personal experiences of adversity and the social and physical 
environment, the ability to predict risk and prevent chronic disease will be further 
improved.
13-15
  As such, powerful mechanisms to combat the chronic disease crisis are 
currently present and continue to evolve.  However, a new healthcare delivery model 
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is needed to implement these mechanisms effectively.  For example, Halfon and 
Hochstein
16
 introduced the Life Course Health Development (LCHD) concept that 
describes “how health trajectories develop over an individual's lifetime due to positive 
and negative experiences and how this knowledge can guide new approaches to 
policy and research.”  One important issue is that early life adversity from poverty, 
abuse and neglect has long lasting influences on health and contributes 
disproportionately to the health care burden.
17
    
An approach in medicine that is preventive, predictive, personalized and 
participatory (P4)
18-25
 holds great promise to reduce the burden of chronic diseases by 
harnessing technology and an increasingly better understanding of human interaction, 
evidence-based interventions and the underlying mechanisms of chronic diseases.  
Current chronic disease management is characterized by the addition of interventions 
and recommendations made by the various medical specialists involved. Minimal 
interactions among specialists and limited information to the general practitioner and 
patient lead to a fragmented health approach, non-concerted and sometimes 
ineffective interventions, a scattered follow-up and a suboptimal cost-effectiveness 
ratio.
26, 27
  The amalgamation of P4 medicine with other prevailing concepts and 
principles has the potential to reinvent healthcare.
28
  In the current concept paper, we 
propose the P4 Health (P4H) continuum model, which embraces and expands upon 
the concepts of P4 medicine
24
, as a framework to promote and facilitate pro-active 
collaborations with a common orchestrated language and integrated care model.  This 
framework draws upon a number of concepts that have been previously established
25, 
29-33
, brought together in a way that augments the potential impact.   
The P4H Continuum Model 
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There is broad agreement that the current framework used to guide healthcare 
and chronic disease management is largely ineffective. As such, there is a need to re-
conceptualize the paradigm to focus on wellness and the prevention of chronic disease 
and associated risk factors first and foremost.  The concept of wellness, an optimal 
state of health, is a paradigm-changing concept for transforming healthcare.  In the 
future, healthcare must shift its focus to promoting a state of wellness, from the 
individual to population level, as well as following wellness to disease transitions and 
learning how to reverse common diseases at their earliest possible stage.  Within the 
coming years, we predict that the ability to better define true human wellness will be 
further refined through advancements in numerous scientific fields including blood 
biomarkers.  In instances where risk factors or an actual chronic disease diagnosis has 
manifested, the focus must shift to aggressively return an individual to a state of 
health and wellness.  Moreover, there is wide agreement that the stakeholders 
involved and the interventions and programming needed to combat chronic disease 
must expand and embrace a multisector approach.
32
   Figure 1 illustrates the P4H 
continuum model; the two central components of this model are Stages of Health and 
Levels of Intervention.  The remaining sections describe core components of the P4H 
continuum model, illustrated in Figure 1, in detail.   
Stages of Health 
The chronic disease trajectory and the transition from health to a chronic 
disease can be divided into four primary stages, based on the model of allostasis and 
allostatic load and overload.
34
  Allostasis is the active process of adaptation to daily 
experiences, good or bad, and allostatic load and overload refers to the cumulative 
change in brain and body that, when an individual experiences “toxic stress”, both 
psychologically and physiologically and lacks control, dysregulation of the mediators 
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that normally promote adaptation and pathophysiology ensues, leading to disease.  
Negative health behaviors related to a stressful lifestyle contribute to allostatic load 
and overload.  In this scheme, initially, an individual moves from health, Stage A, to 
detectable signs, or biological expression, Stage B, where early disease precursors 
and dysfunctions can be detected but the individual is unaware of them and does not 
have any symptoms, which is common in clinical medicine. From Stage B, chronic 
diseases usually progress slowly, the individual showing symptoms, and clinical 
expression Stage C is the point at which traditional reactive health care is initiated.  
Despite advancements in interventions, many individuals with symptoms will make 
the transition to confirmed chronic disease, Stage D, where traditional healthcare is 
continued and up-titrated with pharmacotherapy, surgery and other interventions used 
to manage the chronic disease. Once reaching Stage D and a chronic disease 
diagnosis is confirmed, some degree of permanent physiologic damage/dysfunction 
(i.e., allostatic overload) is likely. For example, ischemic damage after a myocardial 
infarction or stroke, cancer and other chronic diseases will leave permanent damage 
and dysfunctions that, in the current reactive health care system, usually requires 
lifelong treatment and management.  Even so, in those who aggressively attempt to 
improve core components of their health, an individual with a chronic disease 
diagnosis has the potential to significantly improve their prognosis, clinical status and 
quality of life (QoL).  Type II Diabetes is a classic example of development through 
these stages, eventually leading to an irrevocable stage. However, intervention and 
lifestyle management at Stage B or C has the potential to reverse this disease process.  
The following passages describe the stages of health illustrated in Figure 1 in greater 
detail.   
Stage A: Apparently Healthy and Avoiding the Accumulation of Stressors 
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Stage A (i.e., allostasis) indicates an individual is in apparently good health 
and wellness.  Individuals in Stage A emulate healthy lifestyle characteristics [i.e., 
regular physical activity (PA), no tobacco use, nutritious diet, no harmful alcohol use] 
and possess key health measures within the normal range (i.e., blood glucose, BP, 
blood lipids and body habitus).  It is during this stage that individuals are able to 
“adapt to potential threats to their survival and changes in their environment (often 
referred to as “stressors”) in order to maintain homeostasis and promote survival”.35  
The term ‘apparently’ healthy is used because at this time we do not have the tools at 
hand to determine levels of poor health beyond the presence of clinical risk factors.  
There is however research progress in identifying more granular risk categories 
(stages of accelerated aging and early disease risk) in the absence of clinical 
biomarkers.  Such genomics and other detailed biological, clinical, environmental and 
molecular assessments are currently not readily available for assessment for the 
general public.  As our ability to perform detailed molecular assessments for a larger 
percentage of the population evolves, the characterization and definition of apparent 
health in Stage A will become refined and more precise.  Movement in this direction 
has begun with precision medicine initiatives moving forward.
13, 18, 36-38
  Large, dense, 
dynamic, personalized data clouds, such as the one being generated by the 100K 
wellness project
39
, is a specific example of a movement towards precision medicine.  
These efforts are creating the framework for “scientific wellness”40, where millions of 
data points, from DNA, blood, saliva, the microbiome and lifestyle, amongst others, 
will be used to exponentially refine how an individual’s health is managed and 
optimized. 
Unfortunately, those who emulate Stage A health comprise a very small 
percentage of the current global population.
5, 8, 9
  Moreover, most individuals are 
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immersed in a world that is far from what can be characterized as health-promoting.  
In a sense, this poor health environment (e.g., limited access to nutritious food, a 
physically inactive environment and limited effective social network interactions, 
etc.) is a communicable condition.  That is to say the poor health characteristics of an 
environment can be transmitted to an individual.
41-43
 We thus have created a world 
where the ability of an individual to remain in Stage A is increasingly difficult.  A 
global health goal must be directed toward substantially increasing the percentage of 
the population that remains in Stage A health, providing an inoculation from 
unhealthy environments.    
Chronic diseases share a common cluster of environmental and lifestyle risk 
factors or stressors (e.g., physical inactivity, poor nutrition, psychosocial distress, 
excess body mass, indoor and outdoor air and sound pollution, tobacco, inadequate 
sleep, excess stress, etc. ).
4, 5, 44
  Socio-economic determinants, especially poverty, 
also influence the generation, severity and management of chronic diseases.
6, 45
   It is 
usually a constant exposure to these stressors and poor health behaviors that underlie 
the journey toward allostatic overload and resulting chronic disease.  Negative 
stressors, or distress, are complexly associated with sustained local and systemic 
inflammation as well as a host of other dysfunctions.
46, 47
 These stressors can begin 
early in life reflecting effects of abuse, neglect and poverty, with significant negative 
health implications during adulthood that contribute disproportionately to the 
healthcare burden.
48, 49
  Children exposed to adverse childhood experiences (i.e., 
psychosocial, socioeconomic disadvantage, maltreatment and social isolation) are at 
increased risk for depression, increased systemic inflammation and clustered 
metabolic derangements in adulthood.
50
  The cause of a complex set of disorders such 
as chronic diseases cannot be pinpointed to a single origin; rather, a highly complex 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
10 
 
interacting network of many mediators and factors that interact on different levels 
over time and space is involved.
21, 47, 51, 52
 It is also important to note that biological 
systems work in a non-linear way, with the brain as the central organ of adaptation or 
maladaptation.
53
 And with progression along the chronic disease trajectories that is 
cumulative and does not follow a specific timeframe, becoming a unique personalized 
experience for each individual requiring personalized care.
54
  
Certain factors can increase resilience against stressors and maintain an 
individual in Stage A; healthy nutrition and physical activity can reduce the risk of 
cancer and CVD
55, 56
 ; contemplative practices can modulate interception to attenuate 
affective and psychosomatic disorders
57
 and reduce perceived stress and neurogenic 
inflammatory response
58
. Meaning and purpose in life and social connectedness also 
promote better health.
59
  Telomeres provide an example of how these factors can 
impact the rate of biological aging in the absence of disease. Most of these positive 
lifestyle resiliency factors have been related to longer telomere length. Further, a 
positive lifestyle appears to protect telomere shortening when under psychological 
stress.
60, 61
   
Given the right data and aids with interpretation, such preventive activities can 
be effectively personalized to the individual (e.g., providing feedback through 
monitoring).
62
 Beyond a healthy lifestyle, there is still much work to be done with 
how pharmaceutical or other interventions could potentially increase resilience 
towards outside stressors and prevent diseases. It is important to remember that a 
certain amount of positive stress (i.e., eustress) is necessary to maintain health; 
physical exercise and caloric reduction result in eustress, leading to positive 
biological adaptations.
47, 63, 64
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Moving from Stage A (i.e., allostasis) to the beginning of a pre-chronic 
diseaseome
5
, Stage B (i.e., allostatic load), is usually of slow progression and often 
unnoticed by the individual undergoing this transition.  We have studied a prion-based 
mouse model for neurodegeneration with brain transcriptome analyses of 10 time 
points across the entire neurodegenerative process and demonstrated that 4 major 
biological networks become successively disease perturbed—and one can from these 
networks follow beautifully the progression of the disease.  The course of the disease 
lasts 22 weeks, the first clinical signs appear at 18 weeks and the first disease-
perturbed network is seen at 7 weeks—long before any clinical signs.65 As stressors 
accumulate and an individual manifests a greater number of unhealthy lifestyle 
characteristics, the signs of chronic disease risk that define Stage B become 
imminent.  This accumulation of stressors and a failure of biologic resiliency, or 
allostatic load, may be defined as the Stage A-B transition. 
Stage B: The Emergence of Chronic Disease Signs 
The intertwined multitude of stressors most individuals are exposed to in 
Stage A lead to complex phenotypes that eventually manifest as clinical and biologic 
signs.
33
 Stage B marks the initiation of detectable phenomena associated with 
increased chronic disease risk.  Traditional signs include elevated BP, dyslipidemia, 
and elevated blood glucose.
7
  Measures of chronic inflammation
66, 67
 have emerged as 
important signs for chronic disease risk as well, and allostatic load battery that has 
predictive value for later disease brings together measurements of primary and 
secondary mediators of allostasis that can be scored and presented in different 
ways.
68-70
  In fact, the fields of genomics, epigenetics, transcriptomics, proteomics, 
metabolomics and gut microbiome analyses related to chronic disease risk prediction 
are continuing to evolve and future discovery will refine the identification of 
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individuals in Stage B with these parameters.
36, 71, 72
  It is important to note the 
‘omics’ are usually thought of as providing a disease signature but they may be even 
more valuable in the transition from Stage A to Stage B, before there are clear 
underlying signs of allostatic load and clinical biomarkers of disease.  Moreover, the 
importance of a lower than sex/age predicted level in cardiorespiratory fitness and 
muscle strength/endurance are important predictors of future chronic disease risk and 
adverse events.
73-78
  Excess body mass, particularly visceral fat, is also a significant 
predictor of chronic disease risk and associated adverse events.
5, 79-81
  Even so, 
exercise performance and body habitus, while recognized as important markers of 
health and prognosis, are traditionally not viewed as “signs” of chronic disease risk. 
We are proposing a paradigm shift in this mindset and recommend below-normal 
exercise performance and excess body mass be treated as signs of increased chronic 
disease risk and, when present, allow an individual to be classified as Stage B.  
Figure 1 lists examples of Stage B signs that hold significance.  This list of signs is 
kept broadly defined and not intended to be exhaustive but rather an account of 
general themes as research into the optimal combination of signs for identifying risk 
will continue to evolve. Moreover, depending on resources, health professionals may 
not be able to perform an exhaustive assessment of signs and, in such instances, 
should perform assessments using the means they have available.  A great deal of 
information related to an individual’s health, chronic disease risk and prognosis can 
be gained from signs associated with traditional health behaviors and key metrics 
(e.g., physical activity, dietary patterns, BP, lipids, blood glucose, body habitus and 
tobacco use).
7, 82
   
Early dysfunctions and chronic disease pre-cursors as signs of allostatic load 
are often overlooked in the traditional healthcare setting. Individuals with the classic 
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initial signs of chronic disease risk such as high BP, blood glucose and dyslipidemia 
as well as recently discovered signs such as telomere length shortening and changes in 
the gut microbiome usually do not go along with functional impairment in daily life. 
Moreover, diminished exercise performance is also usually undetected in the general 
population – a situation that could be significantly impacted going forward by 
integrating data from the growing set of digital health devices in the marketplace.  
This underperformance in exercise is partly due to the fact that a large percentage of 
the population, particularly those at greatest risk for one or more chronic diseases, 
leads a sedentary lifestyle, avoiding levels of exertion that would likely manifest an 
exertional Stage B sign (e.g. diminished cardiorespiratory fitness and muscle 
strength/endurance).   
Complex dynamical systems, such as human beings, can have tipping points at 
which a sudden shift to a contrasting dynamical regime may occur. Although 
predicting such critical points before they are reached is currently difficult, work in 
different scientific fields is now suggesting the existence of generic early-warning 
signals.
83-85
  Dynamical network biomarker theory (i.e., driver network) was recently 
used to describe upstream, tissue-specific, critical transitions in the liver, adipose 
tissue and muscle that lead to the development and progression of type 2 DM.
86
  The 
monitoring of such early warning signals can help predict the state of disease 
progression and the occurrence of abrupt transitions to a worsening state of health. 
Individuals in Stage B, if engaged, would benefit greatly from a pro-active, 
preventive approach with the goal of eliminating signs and returning an individual to 
Stage A.  At this stage, a particularly important opportunity emerges for the health 
professional to assess the individual’s understanding of health information, assist 
them in appraising and applying critical thinking, and identify obstacles or 
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motivations for the patient to make lifestyle changes. Possible assessment may be 
dictated by the individual’s level of education and language acquisition. Open ended 
questions that lead to discourse analysis may elucidate and encourage the individual’s 
critical thinking skills. Simple narrative collection will shed light on the individual’s 
motivations and goals for their own health.  A variety of media may be used to ensure 
the patient understands the health information through text, visual aids, and verbal 
cues.  
Since most individuals are either unaware of their downhill movement from 
health towards a chronic disease or unwilling to take steps to reverse this trajectory, 
they are unlikely to take preventive, proactive measures, such as lifestyle 
modifications or biological or pharmaceutical interventions.
38, 39, 87
 Emerging efforts 
seek to empower individuals with knowledge to optimize wellness and reverse this 
trajectory.
39, 40
  It will be very important to bring this educational approach to science 
education—so that young adults will already be exposed to these modern insights.  It 
is helpful to view this early health monitoring, psychoeducation, and counseling, as 
critical as early immunizations.  The knowledge and motivation can immunize young 
people from continuing down the silent path of chronic disease.   
In the absence of such, individuals continue to progress along the Stage B 
portion of the continuum; a cluster of signs both silent and those becoming 
increasingly apparent worsen in severity.  After a variable time period, which may 
take decades, Stage B signs will give way to Stage C symptoms (i.e., progressing 
allostatic load). 
Stage C: The Emergence of Chronic Disease Symptoms 
The manifestation of chronic disease symptoms is a common entry point for 
individuals into today’s traditional reactive healthcare system.  For example, dyspnea 
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occurring within the range of exertional capacity needed for activities of daily living 
(e.g., climbing a flight of stairs) is a Stage C symptom.  Persistent depression should 
also be viewed as a symptom that elevates chronic disease risk.
88, 89
  While an official 
chronic disease diagnosis has not yet been made, significant pathophysiologic 
dysfunction is likely well established.  Moreover, unhealthy lifestyle characteristics 
and abnormalities in key health measures are, in the vast majority of cases, also well 
established in Stage C and now compounded by outwardly apparent symptoms.  In 
the traditional reactive healthcare system, the symptoms are oftentimes treated 
without addressing the poorly understood underlying causes and mechanisms that are 
at the root of the dysfunction, which are in large part unhealthy lifestyle behaviors.  
In this sense, this healthcare approach perpetuates the reactive cycle. Symptoms 
become temporarily alleviated as the level of dysfunction persists and progressively 
worsens as do the unhealthy lifestyle behaviors, giving rise to subsequent 
symptomatic episodes and progressive biological damage.  At this point, the risk for 
the eventual diagnosis of a chronic disease and transition to Stage D (i.e., allostatic 
overload) is extremely high.
5, 90
   
Stage D: Confirmed Chronic Disease Diagnosis 
Once a chronic disease is diagnosed (e.g., ICD-coded) the treatment approach 
becomes more aggressive and is the defining moment of the reactive healthcare 
model. Treating a full blown chronic disease, such as coronary artery disease or 
cancer, requires expensive and often invasive interventions. As in Stage C, 
underlying causes and mechanisms of the diagnosed chronic disease are not 
addressed.  The reactive healthcare model is focused on stabilizing the individual in a 
hospital setting and ameliorating acutely elevated symptoms.  Over the last several 
decades, we have become very efficient in this model as indicated by the decrease in 
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annual CVD mortality rates.
5
  Even so, very little is done to address the root cause of 
these conditions.  Even at this stage, environmental and lifestyle risk factors, which if 
modified substantially improve prognosis and quality of life
91
, are usually not 
addressed.  As such, dysfunction continues to spiral downward and symptoms worsen 
with morbidity and premature mortality and increasing healthcare costs as the end 
result.  While this does not have to be the case, once reaching Stage D, individuals 
commonly reside at this stage of health for the remainder of their lives, with a 
coexisting and compounding cluster of Stage B and C signs and symptoms, 
respectively.  Moreover, many individuals are diagnosed with more than one chronic 
disease (i.e., multimorbidity).  In truth, a number of chronic diseases may be capable 
of reversal from Stage D (or even Stage C) back to Stage A (or B). 
Health Stages: Where you have been, where you are now 
 Health Stages A-D should not be viewed as unidirectional or stationary, 
progressing from apparent health to chronic disease with no hope of reversal.  A 
wealth of information clearly demonstrates improving health behaviors and key health 
metrics significantly improves an individual’s future health trajectory.91-93  An 
individual who has been diagnosed with a chronic disease, but aggressively improves 
health metrics and lifestyle behaviors, may ameliorate all Stage C symptoms and 
Stage B signs.  In this case, the individual who was diagnosed with a chronic disease 
(i.e., where they have been) is now demonstrating traits consistent with Stage A 
health (i.e., where they are).  Viewing the stages of health in this manner allows 
individuals to understand the importance of improving health metrics and lifestyle 
behaviors irrespective of baseline health status.  Through active participation, P4 
medicine strives to prevent: 1) the first event/diagnosis from occurring; and 2) 
subsequent events from occurring when a personalized predictive diagnosis has 
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already been made.  Both goals are equally important in the P4H continuum, ensuring 
appropriate care is given to individuals in all stages of health.   
Levels of Intervention  
Moving towards a modern, pro-active health care system, different levels of 
intervention must be clearly defined and the list of stakeholders invested in the 
implementation of the P4H continuum model must be expanded. Health and well-
being depend on a complex fabric of systems that are constantly interacting and 
shaping human biology, behavior and the environment, particularly with respect to 
lifestyle characteristics and chronic disease.  The following sections describe the four 
intervention levels in the P4H continuum model, as illustrated in Figure 1.   
Level I: Global and Country-Based Interventions 
Global and country population strategies, otherwise defined as public health, 
strive to improve the health of a large population and reduce the chronic disease 
burden.  The World Health Organization is the prime example of a global 
organization that has a strong focus in this area, as demonstrated by its initiatives, 
publications related to chronic disease and goals for improvement.
4
  National 
governments are also focused on strategies to improve the health of their populations 
as it relates to chronic disease.
3, 94-98
  Global and whole-country public health 
organizations as well as national/federal governments play a vital role in Level I 
interventions through numerous avenues including: 1) health-promoting legislative 
policies; 2) Financial investment in health-promoting initiatives and research; and 3) 
Policy reports and recommendations.  The WHO has put forth a “health in all 
policies” initiative, encouraging governments to consider the impact of population 
health for all legislations implemented.  This framework is defined as “an approach to 
public policies across sectors that systematically takes in account the health 
AC
CE
PT
ED
 M
AN
US
CR
IP
T
ACCEPTED MANUSCRIPT
18 
 
implications of decisions, seeks synergies, and avoids harmful health impacts, in 
order to improve population health and health equity.”99, 100 An approach such as this 
helps governments to consider Level I health interventions in all actions it takes.     
Level II: Community-Based Interventions 
Despite public health efforts and laws, health-changing behaviors are 
primarily shared across local communities and the environment within them.  Despite 
being categorized as chronic NCDs, to a degree, follow a network pattern. This has 
been shown with obesity and lifestyle-related chronic disease risk behaviors. 
Communities and social networks influence lifestyle patterns and behavior in a 
significant way.
41-43, 101-103
  Level II interventions focus on creating an environment 
where individuals are immersed in a healthy lifestyle environment and readily 
available access to: 1) nutritious and affordable food; 2) opportunities for PA and 
contemplative practice; 3) a smoke free environment; 4) information and resources on 
how to maintain health and prevent chronic disease; and 5) health care systems that 
promote preventive medicine and healthy lifestyle behaviors.  There are numerous 
examples on how to promote healthy lifestyle choices where individuals live, work, 
and attend school.
32, 102, 104-111
  Most of them have not met with outstanding success—
and we have to learn how to persuade individuals to change their misguided or ill-
informed health trajectories towards wellness.
62
  There are also numerous 
opportunities for healthcare systems within a community to practice preventive 
medicine and embrace healthy lifestyle interventions.
112
 
Level III: Individual and Family Unit Interventions 
Ultimately, the delivery of preventive medicine and healthy lifestyle 
interventions must reach and be embraced by a given individual—that is, it must be 
participatory.
20
  In addition to the ultimate goal of Level I and II interventions 
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reaching the individual, Level III interventions continue the P4H continuum care plan 
via face-to-face interactions with health professionals (e.g.., physician, nurse, 
dietician, exercise scientist, pharmacist, behavioral counselor, physical therapist, 
community health worker, wellness coaches, etc.).  Level III interventions are 
directed at the individual as a whole and thus healthy lifestyle interventions are a 
primary focus.  To be effective in delivering Level III healthy lifestyle interventions, 
we must rethink the education of the health professions to ensure all disciplines 
receive the necessary education and training to effectively provide  PA, weight loss, 
dietary or smoking cessation care plans.
113
   
This opens the opportunity for new career trajectories in the healthcare 
professions (i.e., professional wellness coaches). Healthy lifestyle is a universal 
medicine that should be provided by all health professions speaking a universal 
language.  Health professionals delivering Level III interventions greatly benefit from 
effective Level I and II interventions.  If the individual receiving guidance from a 
health professional is immersed in a healthy environment and made well aware of the 
importance of healthy lifestyle through population/community messaging campaigns, 
the ability and likelihood to follow the plan of care is substantially improved.  Level 
III interventions, delivered by a broad array of health professionals, must be 
expanded beyond the traditional walls of the healthcare system (i.e., hospital and 
outpatient clinics).  In particular, to optimally prevent chronic disease, there should be 
a strong focus on delivering Level III interventions in community settings; school 
systems, the workplace, public parks and libraries, grocery stores, pharmacies, in 
addition to traditional outpatient clinics and hospitals, are all appropriate settings for 
Level III interventions.
32, 91, 111, 114
 In this way, Level III interventions reach 
individuals in all stages of health.  Level III interventions must also include the 
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immediate family unit surrounding the individual receiving care.  Adoption of and 
compliance with Level III interventions is optimized if those closest to a given 
individual become invested and believe in the care plan.
32, 115
 In essence, the primary 
“clinic” of Level III interventions is in an individual’s home. 
Level IV: System-Specific Interventions 
Levels I-III interventions focus on the whole individual, promoting 
participation in a healthy lifestyle.  Level IV interventions are system-specific, 
targeting a specific physiologic system within an individual that demonstrates 
abnormal function or chronic disease.  Examples include: 1) pharmacologic 
interventions for hypertension, dyslipidemia or elevated blood glucose and 2) Surgery 
for cancer or CVD.  At this moment, Level IV interventions comprise the majority of 
care delivered in the current reactive healthcare system; most individuals currently 
receiving Level IV interventions are in Stage C and D health, receiving generalized 
care based on current scientific evidence. We are recognizing this generalized 
downstream (i.e., Stage C and D) approach is not optimal.  The National Institutes of 
Health (NIH) has defined precision medicine as "treatment and prevention that takes 
into account individual variability in genes, environment, and lifestyle for each 
person."
116
  As precision medicine advances
13, 18, 117
, opportunities to deliver Level IV 
interventions to individuals in Stage A and B health will evolve and improve the 
ability to deliver P4 medicine.   
All Levels of Intervention for All Stages of Health 
 Given the previously described where you have been – where you are now 
framework, all levels of intervention are essential to all health stages.  No matter what 
health stage an individual enters the P4H continuum model, the primary objective is 
to prevent future chronic disease diagnoses and adverse events, ameliorate symptoms 
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and signs when present, and improve lifestyle behaviors.  In this context, all 
intervention levels should be delivered at all stages of health. 
Stakeholders and Guiding Principles of the P4H Continuum 
 The right-side and lower panels of the P4H continuum illustrated in Figure 1 
highlight stakeholders and overarching guiding principles for the model and are 
described in the following sections.   
The Collaborative Multistakeholder Model 
To realize the full vision of the P4H continuum model, the stakeholder’s 
involved in the future preventive, proactive, healthy lifestyle healthcare system must 
be expanded.  Moreover, to make the impact needed in preventing and treating 
chronic disease, strong collaborations are required amongst stakeholders.
32
  The 
formation of multistakeholder groups, with representatives from all sectors must be 
invested in preventive medicine and healthy lifestyle interventions.  These groups, 
formed within communities, should create innovative programing that is locally 
applicable and effective.  Preventive medicine and healthy lifestyle interventions 
should not be a viewed as a one-size-fits-all approach.  The non-hierarchical 
multistakeholder model outlined in a U.S. – European policy statement32 is an integral 
component of the P4H continuum model and allows for full implementation of all 
levels of intervention across all stages of health.  
P4 Principles Throughout 
Clearly the reactive healthcare model that currently exists is suboptimal, 
requiring a paradigm shift to improve global to individual health and address the 
current challenges we face with chronic disease and associated risk factors.  We need 
a new approach, focusing on care that is preventive, predictive, personalized and 
participatory (P4) as core principles of the P4H continuum model.  Table 1 lists key 
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factors to consider in delivering P4 medicine and subsequent sections describe key 
attributes. 
Predictive 
Predicting dysfunctions and detecting disease pre-cursors at Stage B allows 
for pro-active interventions to address the underlying mechanisms before symptoms 
occur.  Predictive medicine is essential to the preventive framework; when a risk 
factor phenotype manifests, predicting an increased likelihood for adverse events, all 
efforts should be taken to eliminate these risk factors, returning the individual to an 
optimal state of health. This will require a broad array of health care professionals to 
take a more active role in addressing and interacting with ‘healthy individuals’, 
without signs or symptoms, to detect the risk of emerging dysfunctions, preventing a 
progression in stage of health at a minimum and ideally facilitating a regression (i.e., 
back to Stage A). 
A biomarker is an indicator of a biological state, or the past or present 
existence of a particular type of organism. It is not necessarily a genomic or post-
genomic one. Blood lipids are a risk factor for CVD.
118
 However, for many diseases 
(including cancer), clinically useful biomarkers are just beginning to appear and are 
not yet wide spread.
119, 120
 For example, a 13 protein blood panel that has the ability to 
distinguish benign from neoplastic lung nodules has recently been developed; this 
simple expediency can save the healthcare system $3.5 billion a year in avoiding 
unnecessary surgeries.  This is now an available CLIA approved test.
120
 Future 
systems biology research will help to discover new biomolecular networks and 
biomarkers for disease prediction and monitoring. Biomarkers of pharmacogenomics 
and targets will also be of interest to improve bio-pharmaceutical interventions. 
Currently, ‘classic’ biomarkers’ such as blood lipids, blood glucose and C - reactive 
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protein remain at the core of predicting diseases. The next generation of biomarkers 
will increase the precision of identifying dysfunctions, ideally early in the process. 
However, given the complex interaction of the different systems and biomarkers 
inside the human body, a systems-based approach is needed to make better sense of 
the overall biomarker profile instead of looking at individual markers, such as 
cholesterol in isolation.
117, 120-122
  Such an approach has begun in the field of aging, 
where, in young “healthy” people, an algorithm of biomarkers predicts the pace of 
aging and early decline vs single markers.
11
 
Preventive 
It is obvious that preventing chronic disease is the preferred approach moving 
forward. Functional and physiologic health decline in parallel with advancing age 
and/or manifestation of chronic disease and co-morbidity.
123
  Aging currently is 
associated with increases in the likelihood of dysfunctions, chronic diseases and co-
morbidities, thereby confounding their effects on health and well-being. Quality of 
life, autonomy and life expectancy are greatly reduced as the individual progresses 
rightward along the continuum (i.e., Stage A to D).  The slope of the decline in 
functional and physiologic health can be dramatically attenuated through a preventive 
approach.  Health care costs are highest at Stage C and D where Level IV 
interventions are primarily utilized. Preventing diseases as early as possible requires a 
deeper understanding of chronic disease pathogenesis, which comes from employing 
systems medicine approaches that identify relevant disease-perturbed networks
65
, and 
the influence of risk factors as well as potential protective factors.  Ideally, preventing 
disease in Stage A ensures risk factors for chronic disease never manifest (i.e., 
primordial prevention).  If this avoidance were achieved, Stage A would become a 
true stage of health and wellness/well-being as opposed to a doorway to Stage B and 
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beyond.  While primordial prevention should be the ultimate goal, primary and 
secondary prevention are also integral components; regardless of age or health status, 
preventive medicine is highly effective and valuable (i.e., where you have been – 
where you are now).  An overarching goal for the P4H continuum should be, when 
individuals cared for in this model, are asked “where they are now?”, their response is 
Stage A.    
Personalized 
Medicine has traditionally made generalized assumptions regarding the 
individual receiving care without an appreciation of the complexities of human 
biology and its unique interaction with the surrounding environment.  Such a 
generalized approach has led to suboptimal outcomes for a large percentage of 
individuals receiving care.  Research is beginning to illustrate the importance of 
personalized medicine.  For example, personalized nutrition research has revealed 
highly inter-individual responses to standardized meals, illustrating the importance of 
not taking a one-size-fits-all approach.
124
 The response to physical exercise and 
psychological stress is also highly variable and depends on individual genetic profiles 
and lifestyles.
125, 126
 Moreover, chronic disease risk in general has a genetic 
component that is highly individual.
15, 119
 The approach to certain chronic diseases 
such as cancer is already moving towards a more personalized approach based on 
individual phenotyping and molecular targeting.
119
 
Healthcare is also beginning to fully appreciate the ‘non-responder’ 
phenomenon, diving into clinical trials, where statistically significant p-values have 
traditionally denoted interventional success, and identified individuals where 
treatment was ineffective.
125, 126
  This distinction between individual responses is the 
essence of the personalized approach, identifying the non-responder phenotype and 
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creating individualized interventions that break past that barrier.  Personalized 
medicine will need to find ways to provide user-friendly, secure and efficient ICT-
systems to manage the highly diverse, complex and distributed data of the individual 
patient across the entire P4-health continuum. This will empower the individual to 
take ownership on his/her own data and at the same time support the growth of a 
public health knowledge environment where the community benefits from the 
information gathered on its individual members.    
Participatory
20
  
Medicine has a longstanding tradition of a top-down approach. This approach 
might have been useful during times where infectious diseases and acute injures were 
the main health concerns. But with chronic diseases now being the primary health 
crisis, a new approach is needed that involves the individual receiving care, and 
his/her family, as primary stakeholders.
20, 32, 115, 127
 The individual ultimately has to be 
part of the preventive and predictive approach in order to be successful.
62
 Involving 
the individual in personalized treatment and preventive interventions and improved 
data collection through self-tracking will be important factors. To achieve this goal, 
we have to gain a much better understanding of an individual’s “health literacy”.  The 
WHO defines Health Literacy as, “people’s knowledge, motivation and competences 
to access, understand, appraise and apply health information in order to make 
judgements and take decisions in everyday life concerning health care, disease 
prevention and health promotion to maintain or improve QoL during the life 
course”.128 Having an understanding of an individual’s literacy is of paramount 
importance to the participatory component of P4 medicine. Through every stage, 
efforts should be made to assess individual’s motivations and competencies to 
maintain or return to a healthy state. Moreover, aligning the multidirectional flow of 
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health information, between the individual, health professionals and all stakeholders 
immersed within the surrounding environment, is essential to all stages of health and 
all levels of intervention.  Successful and truly participatory approaches with a long 
lasting and sustainable impact will be a major challenge and easier said than done. We 
will need to obtain a much better understanding about the identity, the motives and 
the abilities of the various stakeholders within the P4-health continuum.  Clark et 
al.
129
 have described a framework for crafting usable knowledge for a sustainable 
development that takes into account stakeholder collaboration, social learning, 
knowledge governance and researcher training. Although developed primarily in the 
context of climate or ecosystems, the principles and lessons learned might very well 
be applied to the upcoming transformations in healthcare.   
Leveraging Technology   
The use of technology to continually engage individuals in preventive 
medicine and healthy lifestyle messaging, information and interventions is vital 
moving forward.
37, 38, 130
  Health-focused platforms continue to emerge and evidence 
demonstrating the meaningful impact of technology-based healthy lifestyle 
interventions is continually growing.
131-134
  There is particular value potential in 
utilizing the smartphone platform for continual engagement centered on preventive 
medicine and healthy lifestyle messaging and interventions.
135
 Moreover, the use of 
well-designed technologic platforms has the potential to create individually tailored 
public health messaging.  All stakeholders involved in the P4H continuum model 
should utilize technology to expand the reach and impact of initiatives and 
interventions.  With advances in technology, there may even be a role for 
characterizing levels of robust health (vs. disease risk) in Stage A, which both adds a 
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motivational goal to strive for as well as adds further leverage to the ability to 
measure and promote prevention.     
Systems Medicine and the Complexity of Chronic Diseases 
An old Indian story talks about a group of blind men coming across an 
elephant. Each of the blind men touched a different part of the elephant and gave a 
description of what he believed an elephant was. The first person touched the 
elephant’s trunk and claimed the elephant to be a snake. The second person touched 
the elephant’s leg and declared the elephant to be a tree trunk. Then the last person 
came forward, touched the elephant’s ear and positively identified the elephant to be a 
sail. Based on the blind men’s confined level of interaction with the elephant, their 
observations made sense. However, if they had collaborated and studied the elephant 
globally, its true structure would have become apparent.  
Understanding systems as complex as the human body has to involve 
interactive collaboration between specialists from different fields.  For many years, 
biologists have been studying specific proteins and molecular networks individually, 
describing local interactions and perturbations in detail. Indeed, understanding the 
individual components is an important first step, but, to truly understand complex 
biological systems, an integrated approach must be taken. Therefore, a common, 
orchestrated language that allows specialists to speak and communicate with ease 
should be standard in training curricula, or a specialist trained in communicating 
between specialties should be included whenever possible.  Further, a variety of data 
at all relevant levels of cellular organization with clinical and individual reported 
disease markers have to be integrated using the power of computational and 
mathematical modelling, to enable the understanding of the mechanisms, prediction, 
prevention and treatment of disease.
121
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Modern medicine has to take into account that the human biological system is 
a collection of networks at multiple levels, ranging from the molecular level, through 
cells, tissues and organisms, to the population level. Years of research have generated 
detailed information about the components of the complex systems that characterize 
ecosystems, life, organisms, genes, and cells; this knowledge has begun to fuse into 
greater understanding of how all those components work together as systems.
121, 124
 
P4 and systems medicine take global, integrated and quantified approaches to the 
challenge of biological complexity. Systems medicine uses high throughput 
technologies – such as DNA and RNA sequencing – to produce global data sets 
tracking multiple dimensions of dynamic network interactions to better predict and 
prevent chronic disease.
15, 71
 Enormous amounts of data obtained by tracking multiple 
biological networks are integrated to create a comprehensive understanding of human 
biology. For example, with this information scientists can begin to understand how an 
individual’s genetic makeup and environment together produce health and disease.14, 
37, 38, 64, 136
 Modern medicine requires a new infrastructure described in Table 2 as the 
‘five pillars’ of systems-based P4 medicine. 
Convergence of Principles from Eastern and Western Medicine 
Eastern medicine, like P4 medicine and systems medicine, considers human 
biological systems as a cohesive whole.  Eastern medicine also considers the human 
body as a holistic entity of harmonious organs and approaches health from this 
framework.  Eastern medicine principles are mainly derived from Chinese and Indian 
cultures, with long-term practical experience in the prevention, diagnosis and 
treatment of chronic diseases. 
Principles of Chinese Medicine and Its Role in the P4H Continuum 
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Traditional Chinese medicine has evolved over thousands of years and 
represents one of the oldest paradigms of translational medicine in the world.
137
 
Chinese traditional medicine considers the human body as an open organism 
operating in a continuous biological and mental exchange process with the outside 
environment; human health is maintained by the balance between Yin and Yang that 
respectively represents two opposing factors in nature.
138
 The diagnosis and stages of 
health (i.e., Stage A), risk (i.e., Stages B-C) and disease (i.e., Stage D) are 
established based on signs and symptoms, physical and psychological status of an 
individual and environmental factors that may modify homeostasis of the human body. 
The therapeutic approaches of chronic diseases include: 1) a primary medical 
prescription that targets the causative abnormality or the main symptom; 2) other 
remedies for treating secondary disorders or symptoms that enhance the efficacy of 
the primary intervention; and 3) eliminate toxicity associated with the primary 
medical prescription or pathogenic factors from the external environment.  In the P4H 
continuum model, the Yin and Yang view on human health could be further 
considered for staging chronic disease trajectory and the transition from health to a 
chronic disease, as well as intervention strategies directed toward optimizing health 
stage through modulating the balanced points at physical and psychological levels.
139
 
Currently, in China, traditional Eastern medicine has been integrated into the 
Country-, Community-, Family-, and Individual-based healthcare system, which 
serves as a complement to modern Western medicine. In the era of modern P4 
medicine, Eastern medicine could enhance chronic disease prevention and 
management through its view of the integration of complex systems of the human 
body, psychological stresses, lifestyle patterns and the environment in an optimal 
cost-effective manner.     
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Principles of Indian Medicine (Ayurveda) and Its Role in the P4H Continuum 
Ayurveda basically means “Knowledge (Veda)” of “Life (Ayur)”. Ayurveda is 
an ancient system of personalized medicine documented and practiced in India since 
1500 B. C.
140
 Today, Ayurveda not only plays a key role in Asian health care systems 
but is also increasingly recognized in the European and North American model.
141
 
A unique aspect of Ayurveda is the comprehensive understanding of the 
biological basis of human individuality through Prakriti (literally meaning basic 
nature or the healthy state – Stage A). According to Ayurveda, an individual is born 
with a specific Prakriti that not only determines an individual’s overall phenotype but 
also predicts the susceptibility to diseases and responsiveness to extrinsic and intrinsic 
environments.
140
  Assessment of the disease state (Vikriti) and treatment in the 
Ayurveda system depends on “where you were and where you are now” with respect 
to an individual’s own Prakriti and how far enhancement of specific Dosha has 
occurred to create imbalance leading to a state of Vikriti (i.e., Stages B-D). Ayurvedic 
medicine treats individuals holistically in combination of medicine, diet and lifestyle 
management (Yoga and other exercises) with the goal of returning to one’s original 
state of Prakriti (i.e., Stage A).  In this context, Ayurvedic system of medicine draws 
several parallels to the prevailing concepts of P4 medicine.  
Over the last decade, major efforts have been initiated in India to establish the 
molecular correlation with specific Prakriti. These efforts in translating the concepts 
of P4 medicine and establishing the relationship of phenotypic classification of 
Ayurveda with modern genomic analysis has led to the convergence of two 
disciplines and emergence of the new field of Ayurgenomics.
142-144
 Attempts are 
being made to correlate differences in epigenetic markers (DNA methylation) with 
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various Prakriti phenotypes
145
 along with Genome-Wide SNP Analysis as correlates 
of Ayurveda Prakriti
146
. 
The P4H Continuum: Impacts from Population to Cellular Health 
The key benefits of the P4H continuum model, from the population to cellular 
level, include the following examples: 1) Prevent the occurrence of chronic diseases 
and associated risk factors by implementing effective interventions at all levels; 2) 
Detect and predict disease at an early stage, when it can be controlled and reversed 
effectively; 3) Stratify individuals into refined specific disease phenotypes, enabling 
the selection of optimal therapies; 4) Reduce adverse drug reactions through the early 
assessment of individual drug responses; 5) Improve the selection of new biochemical 
targets for interventions; and 6) Shift the emphasis in medicine from reactive to 
proactive prevention and from disease to health, including enhancing wellness in 
disease-free individuals. Table 3 describes the key paradigm shifts from a reactive to 
proactive P4H continuum model.  The authors of this concept paper are proposing the 
model described herein become the framework for combating the chronic disease 
crisis we currently face. 
Conclusion 
To address chronic diseases globally and in their totality, and in order to 
reduce their burden and societal impact, medicine has to evolve from a reactive to a 
proactive system, the latter of which is committed to a healthy aging process (i.e., 
lengthening the healthspan). It is proposed that chronic diseases should be viewed as a 
single expression (i.e., chronic diseaseome) with common risk factors and themes. 
Efforts to make healthcare more predictive, preventive, personalized and participatory 
(i.e., P4 medicine) will greatly improve health and well-being across the health 
continuum. The introduction of a systems-approach, continually capitalizing on the 
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most recent technologic advances as well as the requirement of more interdisciplinary 
work, require an orchestrated language to help researchers, healthcare professionals 
and stakeholders across a multitude of sectors to collaborate as efficiently as possible. 
We can also use systems approaches to understand the most common morbidities and 
why they are related and how to simultaneously reverse these shared conditions.  The 
authors of this concept paper hope that the model proposed herein helps to spur the 
needed paradigm shift, with a focus on maintaining allostasis, wellness and 
prolonging the healthspan. 
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Table 1: P4 Concepts of Chronic Disease Severity, Activity, Control and 
Responsiveness  
 
Severity 
Loss of function in the target organs induced by disease. It is important to highlight 
that severity may vary over time and needs to be regularly re-evaluated, in 
particular since the population is ageing. Notably, temporal fluctuations of disease 
markers may provide a diagnostic or phenotypic signal by themselves. 
 
Activity 
Level of biological process activation that drives disease progression. This is a 
fundamental concept that needs to be clearly separated from “severity” because 
treatment strategies are different. Hence, whereas treatment of disease activity aims 
at stopping and/or reducing the progression of the disease, thus eventually avoiding 
the occurrence of severe disease, treatment of severity aims at palliating the impact 
of the disease on the patient’s health status. Current management of chronic 
diseases focuses on treatment of severity but neglects treatment of activity because 
of the lack of validated activity biomarkers.  
 
Control 
Degree to which therapy goals are currently met such as glycemic control in 
diabetes. The lack of validated biomarkers of disease activity limits their use in 
most chronic diseases. 
 
Responsiveness 
Ease with which control is achieved by therapy. Adherence to therapy is a key 
component of responsiveness and should also be monitored. 
 
Source: 
Bousquet J, Jorgensen C, Dauzat M, Cesario A, Camuzat T, Bourret R, Best N, Anto JM, Abecassis F, 
Aubas P, Avignon A, Badin M, Bedbrook A, Blain H, Bourdin A, Bringer J, Camu W, Cayla G, Costa 
DJ, Courtet P, Cristol JP, Demoly P, de la Coussaye JE, Fesler P, Gouzi F, Gris JC, Guillot B, Hayot 
M, Jeandel C, Jonquet O, Journot L, Lehmann S, Mathieu G, Morel J, Ninot G, Pelissier J, Picot MC, 
Radier-Pontal F, Robine JM, Rodier M, Roubille F, Sultan A, Wojtusciszyn A, Auffray C, Balling R, 
Barbara C, Cambon-Thomsen A, Chavannes NH, Chuchalin A, Crooks G, Dedeu A, Fabbri LM, 
Garcia-Aymerich J, Hajjam J, Melo Gomes E, Palkonen S, Piette F, Pison C, Price D, Samolinski B, 
Schunemann HJ, Sterk PJ, Yiallouros P, Roca J, Van de Perre P and Mercier J. Systems medicine 
approaches for the definition of complex phenotypes in chronic diseases and ageing. From concept to 
implementation and policies. Current pharmaceutical design. 2014;20:5928-44. 
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Table 2: The Five Pillars of P4 Medicine 
 
Pillar 1 
■ Cutting-edge technologies for generating data regarding multiple dimensions of 
each person’s experience of health and disease. 
Pillar 2 
■ A digital infrastructure linking participating discovery science and clinical 
institutions, as well as patients/consumers. 
 
Pillar 3 
■ Personalized data clouds providing information about multiple dimensions of each 
individual’s unique dynamic experience of health and disease ranging from the 
molecular to the social. These data will include genetic and phenotypic 
characteristics, medical history, demographics and other sociometrics. 
 
Pillar 4 
■ New analytic techniques and technologies from deriving actionable knowledge 
from the data. 
 
Pillar 5 
■ Systems biology models for understanding the unique health status of each 
individual in terms of dynamic network states that can be manipulated by cost-
effective strategies 
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Table 3: Paradigm Shifts from Reactive to Proactive Medicine 
 
Reactive Medicine Proactive P4 Medicine 
Reactive 
Symptoms based response 
Proactive and preventive 
Pre-symptomatic biomarker response 
Cross-sectional Disease Management Lifespan Health Management 
Few measurements, limited diagnostic 
and prognostic value 
Many measurements, high resolution 
diagnostic and prognostic value 
Organ-centric Systems-Biology 
Disease-centric Person-centric 
Based on needs, personal requirements 
and biological variability 
Symptom focused therapy Disease mechanism focused 
therapy/interventions 
Top-Down  Individual and health professional as a 
team 
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Figure 1: The P4H Continuum Model 
 
Figure attached in separate file 
 
 
